Blog

Bernard A. Fox: Fighting for better funding for lung cancer research

Bernard Fox/Chiles Research Institute-X

Dec 8, 2024, 13:05

Bernard A. Fox: Fighting for better funding for lung cancer research

Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post by Stand Up To Cancer on LinkedIn, adding the following:

“Cancer is a horrible disease! I am in Napoli for my 4th day of Bridge2024, which is a cancer meeting organized by Paolo A. Ascierto and which primarily focuses on cancer immunotherapy.

I just read Susan’s words and thought some data were worth sharing upfront for people who might not click on the link:

Susan said, ‘It is not well known that lung cancer is the number one cause of cancer death in women and the second most common cancer in women. Although lung cancer overall is decreasing because of declines in tobacco use, lung cancer among people who have never smoked has been rising significantly, and two-thirds of people diagnosed with lung cancer with no smoking history are women.

Despite lung cancer being the leading cause of cancer death in the U.S., it’s significantly underfunded. Lung cancer receives $4,438 per death in NIH research funding, whereas breast cancer receives $19,869, prostate $9,135, colorectal $7,565, and pancreatic $5,932 (source). I plan to raise awareness and fight for more resources for lung cancer patients overall.’

RIP Susan.”

Quoting Stand Up To Cancer‘s post:

“Former YouTube CEO Susan Wojcicki passed away at the age of 56 after a two-year battle with non-small cell lung cancer. She was a mother of five, an incredibly successful businesswoman, and fierce advocate for lung cancer research. While in treatment, Susan wrote a blog about her cancer journey and how it changed her. In it, Susan advocates for more funding for lung cancer research and the importance of new treatments. In her memory and in honor of Lung Cancer Awareness Month, we encourage you to read her words.”

Bernard A. Fox is the Co-Founder, President, and CEO of UbiVac. He is an Adjunct Professor in the Department of Molecular Microbiology and Immunology, at the Knight Cancer Institute. He is also a Member of Board of Directors at Oregon Bioscience Association.In 2012, Dr. Fox received the Harder Family Endowed Chair for Cancer Research in recognition of his efforts in translational cancer therapy.